06
Jan

San Diego biotech Tracon is lining up for a $57.5 million IPO to bankroll an ambitious program for its lead cancer drug, with major shareholder New Enterprise Associates lighting the way.

…read more

Source: Tracon eyes a $57.5M IPO to get its cancer drug into Phase III

    

0 No comments